Securian Asset Management Inc. Has $487,000 Stock Holdings in Solventum Co. (NYSE:SOLV)

Securian Asset Management Inc. decreased its holdings in shares of Solventum Co. (NYSE:SOLV) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,374 shares of the company’s stock after selling 164 shares during the quarter. Securian Asset Management Inc.’s holdings in Solventum were worth $487,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of SOLV. Principal Financial Group Inc. boosted its holdings in Solventum by 3.0% in the third quarter. Principal Financial Group Inc. now owns 169,615 shares of the company’s stock worth $11,826,000 after purchasing an additional 4,896 shares in the last quarter. Atria Investments Inc lifted its position in shares of Solventum by 93.2% in the third quarter. Atria Investments Inc now owns 11,699 shares of the company’s stock worth $816,000 after buying an additional 5,644 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Solventum by 137.3% during the 3rd quarter. Victory Capital Management Inc. now owns 53,589 shares of the company’s stock worth $3,736,000 after acquiring an additional 31,007 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in shares of Solventum during the 3rd quarter valued at about $315,000. Finally, CIBC Asset Management Inc raised its stake in shares of Solventum by 7.9% in the 3rd quarter. CIBC Asset Management Inc now owns 19,291 shares of the company’s stock valued at $1,345,000 after acquiring an additional 1,408 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have commented on SOLV shares. Bank of America increased their price target on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a report on Wednesday, February 26th. Morgan Stanley raised their target price on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Piper Sandler upped their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Mizuho raised their price target on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday, March 3rd. Finally, The Goldman Sachs Group boosted their price objective on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $79.86.

Solventum Trading Up 1.2 %

Solventum stock opened at $75.04 on Tuesday. The business has a 50 day moving average price of $74.65 and a two-hundred day moving average price of $71.30. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $85.92. The stock has a market cap of $12.98 billion and a price-to-earnings ratio of 27.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.